Accurate, affordable non-invasivedetection of fetal trisomies with a smiple maternal blood draw performed after 10 weeks' gestation Traditional prenatal screening can pose challenges for healthcare providers and their patients. With up to 30% false negative rates and 5% false positive rates, current screening can lead hundreds of thousands of women to undergo unnecessary invasive procedures and risk fetal loss. However, with the advent of DNA sequencing and other technological advancements over the last three decades, one of the greatest leaps forward in molecular diagnostics has been the introduction of "NIPT" or non-invasive prenatal testing. NIPT offers pregnant patients as early as 10 weeks' gestation an accurate and personalized method of detecting fetal trisomies linked to Down syndrome and others conditions.   The Harmony blood test is capable of reliably identifying and counting cell-free DNA fragments in maternal blood, determining whether a fetal trisomy may be present. Ariosa, Harmony, and Harmony Prenatal Test are trademarks of Ariosa Diagnostics, inc.